PharmaEngine (4162) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.011x

Based on the latest financial reports, PharmaEngine (4162) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.01 Million ≈ $1.67 Million USD) by net assets (NT$4.79 Billion ≈ $151.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of PharmaEngine for the company's overall valuation and market capitalisation.

PharmaEngine - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how PharmaEngine's cash flow conversion efficiency has evolved over time, based on yearly financial data.

PharmaEngine Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PharmaEngine ranked by their cash flow conversion efficiency. Explore 4162 cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Graf Global Corp NYSE MKT:GRAF	0.000x
Te Chang Construction Co Ltd TWO:5511	0.048x
GNA Axles Limited NSE:GNA	0.151x
Pecca Group Bhd KLSE:5271	0.122x
Churchill Capital Corp X Class A Ordinary Shares NYSE:CCCX	0.023x
Dustin Group AB ST:DUST	0.054x
H+H International A/S CO:HH	0.054x
Skel fjárfestingafélag hf. IC:SKEL	-0.001x

Annual Cash Flow Conversion Efficiency for PharmaEngine (2009–2024)

The table below shows the annual cash flow conversion efficiency of PharmaEngine from 2009 to 2024. View current stock price of PharmaEngine for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.40 Billion ≈ $170.12 Million	NT$456.73 Million ≈ $14.39 Million	0.085x	+27.15%
2023-12-31	NT$3.86 Billion ≈ $121.70 Million	NT$256.97 Million ≈ $8.10 Million	0.067x	+27.51%
2022-12-31	NT$3.87 Billion ≈ $121.99 Million	NT$202.01 Million ≈ $6.36 Million	0.052x	-77.90%
2021-12-31	NT$3.94 Billion ≈ $124.09 Million	NT$929.67 Million ≈ $29.29 Million	0.236x	+1361.78%
2020-12-31	NT$4.01 Billion ≈ $126.37 Million	NT$64.77 Million ≈ $2.04 Million	0.016x	+249.80%
2019-12-31	NT$3.48 Billion ≈ $109.73 Million	NT$16.08 Million ≈ $506.55K	0.005x	-97.71%
2018-12-31	NT$3.69 Billion ≈ $116.38 Million	NT$745.23 Million ≈ $23.48 Million	0.202x	+332.53%
2017-12-31	NT$3.91 Billion ≈ $123.22 Million	NT$-339.30 Million ≈ $-10.69 Million	-0.087x	-137.86%
2016-12-31	NT$3.80 Billion ≈ $119.68 Million	NT$870.38 Million ≈ $27.42 Million	0.229x	+61.57%
2015-12-31	NT$3.16 Billion ≈ $99.53 Million	NT$447.99 Million ≈ $14.11 Million	0.142x	+216.59%
2014-12-31	NT$2.93 Billion ≈ $92.20 Million	NT$131.09 Million ≈ $4.13 Million	0.045x	+357.03%
2013-12-31	NT$2.72 Billion ≈ $85.63 Million	NT$-47.37 Million ≈ $-1.49 Million	-0.017x	-141.46%
2012-12-31	NT$1.63 Billion ≈ $51.45 Million	NT$68.64 Million ≈ $2.16 Million	0.042x	-90.56%
2011-12-31	NT$618.48 Million ≈ $19.49 Million	NT$275.49 Million ≈ $8.68 Million	0.445x	+163.34%
2010-12-31	NT$81.42 Million ≈ $2.57 Million	NT$-57.26 Million ≈ $-1.80 Million	-0.703x	+91.23%
2009-12-31	NT$11.29 Million ≈ $355.76K	NT$-90.54 Million ≈ $-2.85 Million	-8.018x	--

About PharmaEngine

TWO:4162 Taiwan Biotechnology

Market Cap

$249.07 Million

NT$7.91 Billion TWD

Market Cap Rank

#15773 Global

#714 in Taiwan

Share Price

NT$55.80

Change (1 day)

+2.20%

52-Week Range

NT$53.00 - NT$73.80

All Time High

NT$178.54